MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 121095 | Name: Selvigaltin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Selvigaltin, also known as GB0139, is a galectin-3 inhibitor. GB0139 protects against acute lung injury by inhibiting neutrophil recruitment and activation. B0139 decreased inflammation severity via a reduction in neutrophil and macrophage recruitment and neutrophil activation. GB0139 reduced LPS-mediated increases in interleukin (IL)-6, tumor necrosis factor alpha (TNFα) and macrophage inflammatory protein-1-alpha. In vitro, GB0139 inhibited Gal-3-induced neutrophil activation, monocyte IL-8 secretion, T cell apoptosis and the upregulation of pro-inflammatory genes encoding for IL-8, TNFα, IL-6 in alveolar epithelial cells in response to mechanical stretch.

Chemical Structure

Selvigaltin
CAS#1978336-95-6

Theoretical Analysis

MedKoo Cat#: 121095

Name: Selvigaltin

CAS#: 1978336-95-6

Chemical Formula: C19H16BrF3N4O4S

Exact Mass: 532.0028

Molecular Weight: 533.32

Elemental Analysis: C, 42.79; H, 3.02; Br, 14.98; F, 10.69; N, 10.51; O, 12.00; S, 6.01

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Selvigaltin; GB0139; GB-0139; GB 0139
IUPAC/Chemical Name
5-bromopyridin-3-yl 3-deoxy-1-thio-3-[4-(3,4,5- trifluorophenyl)-1H-1,2,3-triazol-1-yl]-α-Dgalactopyranoside
InChi Key
FNCLKJPMEFPXOR-QFACEVIFSA-N
InChi Code
InChI=1S/C19H16BrF3N4O4S/c20-9-3-10(5-24-4-9)32-19-18(30)16(17(29)14(7-28)31-19)27-6-13(25-26-27)8-1-11(21)15(23)12(22)2-8/h1-6,14,16-19,28-30H,7H2/t14-,16+,17+,18-,19-/m1/s1
SMILES Code
BrC1=CN=CC(S[C@H]2O[C@H](CO)[C@H](O)[C@H](N3C=C(C4=CC(F)=C(F)C(F)=C4)N=N3)[C@H]2O)=C1
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 533.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Zetterberg FR, MacKinnon A, Brimert T, Gravelle L, Johnsson RE, Kahl-Knutson B, Leffler H, Nilsson UJ, Pedersen A, Peterson K, Roper JA, Schambye H, Slack RJ, Tantawi S. Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease. J Med Chem. 2022 Oct 13;65(19):12626-12638. doi: 10.1021/acs.jmedchem.2c00660. Epub 2022 Sep 26. PMID: 36154172; PMCID: PMC9574852. 2: Tabel M, Wolf A, Szczepan M, Xu H, Jägle H, Moehle C, Chen M, Langmann T. Genetic targeting or pharmacological inhibition of galectin-3 dampens microglia reactivity and delays retinal degeneration. J Neuroinflammation. 2022 Sep 17;19(1):229. doi: 10.1186/s12974-022-02589-6. PMID: 36115971; PMCID: PMC9482176. 3: Humphries DC, Mills R, Boz C, McHugh BJ, Hirani N, Rossi AG, Pedersen A, Schambye HT, Slack RJ, Leffler H, Nilsson UJ, Wang W, Sethi T, Mackinnon AC. Galectin-3 inhibitor GB0139 protects against acute lung injury by inhibiting neutrophil recruitment and activation. Front Pharmacol. 2022 Aug 8;13:949264. doi: 10.3389/fphar.2022.949264. PMID: 36003515; PMCID: PMC9393216. 4: Gaughan EE, Quinn TM, Mills A, Bruce AM, Antonelli J, MacKinnon AC, Aslanis V, Li F, O'Connor R, Boz C, Mills R, Emanuel P, Burgess M, Rinaldi G, Valanciute A, Mills B, Scholefield E, Hardisty G, Findlay EG, Parker RA, Norrie J, Dear JW, Akram AR, Koch O, Templeton K, Dockrell DH, Walsh TS, Partridge S, Humphries D, Wang-Jairaj J, Slack RJ, Schambye H, Phung D, Gravelle L, Lindmark B, Shankar- Hari M, Hirani N, Sethi T, Dhaliwal K. An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE). Am J Respir Crit Care Med. 2023 Jan 15;207(2):138-149. doi: 10.1164/rccm.202203-0477OC. PMID: 35972987; PMCID: PMC9893334. 5: Humphries DC, Mills R, Dobie R, Henderson NC, Sethi T, Mackinnon AC. Selective Myeloid Depletion of Galectin-3 Offers Protection Against Acute and Chronic Lung Injury. Front Pharmacol. 2021 Aug 30;12:715986. doi: 10.3389/fphar.2021.715986. PMID: 34526900; PMCID: PMC8435800. 6: Kumar A, Paul M, Panda M, Jayaram S, Kalidindi N, Sale H, Vetrichelvan M, Gupta A, Mathur A, Beno B, Regueiro-Ren A, Cheng D, Ramarao M, Ghosh K. Molecular mechanism of interspecies differences in the binding affinity of TD139 to Galectin-3. Glycobiology. 2021 Nov 18;31(10):1390-1400. doi: 10.1093/glycob/cwab072. PMID: 34228782. 7: St-Gelais J, Denavit V, Giguère D. Efficient synthesis of a galectin inhibitor clinical candidate (TD139) using a Payne rearrangement/azidation reaction cascade. Org Biomol Chem. 2020 May 27;18(20):3903-3907. doi: 10.1039/d0ob00910e. PMID: 32400847.

View History

Benzyl-PEG6-alcohol

Benzyl-PEG6-alcohol

Featured